<DOC>
	<DOCNO>NCT00862524</DOCNO>
	<brief_summary>This 2-phase study patient advanced/metastatic solid tumor receive investigational study drug ARRY-334543 gemcitabine . The study 2 part . In first part study , Phase 1 , patient advanced/metastatic solid tumor receive increase dos study drug combination gemcitabine order achieve high dose study drug possible cause unacceptable side effect . Patients follow see side effect combination cause effectiveness combination , , treat cancer . Approximately 24 patient US enrol Part 1 ( Completed ) . In second part study , Phase 2 , patient metastatic pancreatic cancer receive best dose study drug , combination gemcitabine , determine first part study follow see side effect combination cause effectiveness combination , , treat cancer . Approximately 42 patient US enrol Part 2 ( Withdrawn ) .</brief_summary>
	<brief_title>A Study ARRY-334543 Gemcitabine Patients With Advanced Cancer Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Key Inclusion Criteria ( Part 1 ) : Histologically cytologically confirm diagnosis solid tumor suitable treatment gemcitabine . No 3 prior anticancer regimen advance disease . Measurable evaluable , nonmeasurable disease . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 . Able take retain oral medication . Additional criterion exist . Key Exclusion Criteria ( Part 1 ) : Uncontrolled symptomatic brain metastasis ( patient brain metastasis steroid , steroid dose must stable least 30 day ) . Treatment prior chemotherapy within 21 day first dose study drug . Requiring IV alimentation . Pregnancy lactation . Known positive serology human immunodeficiency virus ( HIV ) , hepatitis B and/or hepatitis C. History unable tolerate gemcitabine component . Additional criterion exist .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>